复方胃肠安调控肿瘤相关巨噬细胞铁死亡抑制胃癌的作用探讨OA
Mechanisms of Compound Weichang'an in Inhibiting Gastric Cancer via Regulating Tumor-Associated Macrophage Ferroptosis
目的 探讨复方胃肠安调控肿瘤相关巨噬细胞(tumor-associated macrophages,TAMs)铁死亡抑制胃癌的作用机制.方法 动物实验建立人胃癌裸鼠原位移植瘤模型,将15只雌性裸小鼠(BALB/C)按随机数字表法分为复方胃肠安组、氟尿嘧啶(5-fluorouracil,5-FU)组、模型组,每组5只.复方胃肠安组以41.86 g/kg灌胃给药,5-FU组以90 mg/kg腹腔注射,模型组予等量生理盐水,连续干预21 d,取胃原发灶,计算抑瘤率.细胞实验另取3只健康雌性裸小鼠(BALB/C),用于制备复方胃肠安含药血清.采用佛波酯诱导THP-1细胞分化为M0巨噬细胞,模拟TAMs模型,将其分为复方胃肠安含药血清组、5-FU组和对照组.采用细胞计数试剂盒-8(cell counting kit-8,CCK-8)法检测各组TAMs活力,并确定含药血清最适给药浓度.采用铁离子比色法检测TAMs中亚铁离子(Fe2+)含量;采用2',7'-二氯二氢荧光素二乙酸酯荧光探针观察TAMs活性氧(reactive oxygen species,ROS)荧光信号;采用流式细胞术和JC-1试剂盒检测TAMs线粒体膜电位水平;采用蛋白质免疫印迹法(Western blot)检测TAMs铁死亡相关蛋白谷胱甘肽过氧化物酶4(glutathione peroxidase 4,GPX4)、溶质载体家族7成员11(solute carrier family 7 member 11,SLC7A11)、酰基辅酶A合成酶长链家族成员 4(acyl-CoA synthetase long-chain family member 4,ACSL4)表达水平.结果 动物实验结果显示,复方胃肠安对胃原位移植瘤的抑制率为49%.细胞实验结果显示,与对照组比较,不同浓度复方胃肠安含药血清组TAMs活力降低(P<0.05,P<0.01);复方胃肠安含药血清组TAMs中Fe2+含量升高、ROS含量增加、线粒体膜电位降低(P<0.05,P<0.01),GPX4和SLC7A11蛋白表达升高、ACSL4蛋白表达降低(P<0.01).结论 复方胃肠安可抑制胃癌,其机制可能与促进TAMs铁死亡有关.
Objective To explore the mechanisms by which Compound Weichang'an Decoction inhibits gastric cancer by promoting tumor-associated macrophages(TAMs)ferroptosis.Methods Animal experiment:An orthotopic transplantation tumor model of human gastric cancer was established in nude mice.Fifteen female BALB/c nude mice were divided into a Compound Weichang'an group,a 5-fluorouracil(5-FU)group,and a model group by the random number table method,with five mice in each group.Cell experiment:The Compound Weichang'an Decoction group was administered Compound Weichang'an Decoction at 41.86 g/kg via gavage,the 5-FU group was administered 5-FU at 90 mg/kg via intraperitoneal injection,and the model group was administered an equivalent volume of normal saline.After 21 consecutive days of treatment,all mice were euthanized,and gastric tumors in primary lesions were harvested to calculate the tumor inhibition rate.Additionally,three healthy female BALB/c nude mice were used to prepare Compound Weichang'an Decoction-containing serum.THP-1 cells were induced by phorbol 12-myristate 13-acetate(PMA)to differentiate into M0 macrophages,serving as a TAMs model.Then,this model was divided into a Compound Weichang'an Decoction-containing serum group,a 5-FU group,and a control group.Cell viability of TAMs in each group was detected using the Cell Counting Kit-8(CCK-8)assay to identify the optimal concentration of Compound Weichang'an Decoction-containing serum.Subsequently,ferrous ion(Fe2+)content in TAMs was measured via ferrous ion colorimetry.The fluorescence signal of reactive oxygen species(ROS)in TAMs was detected using the 2',7'-dichlorodihydrofluorescein diacetate(DCFH-DA)fluorescent probe.Mitochondrial membrane potential was evaluated by flow cytometry and the JC-1 kit.Finally,Western blot was employed to determine the expression levels of ferroptosis-related proteins,including glutathione peroxidase 4(GPX4),solute carrier family 7 member 11(SLC7A11),and acyl-CoA synthetase long-chain family member 4(ACSL4).Results Animal experimental results showed that:Compound Weichang'an Decoction demonstrated an inhibition rate of 49%against gastric orthotopic transplantation tumors.Cell experimental results showed that:Compared with the control group,the Compound Weichang'an Decoction-containing serum groups at different concentrations exhibited reduced TAMs viability(P<0.05,P<0.01).Compound Weichang'an Decoction-containing serum group showed increased Fe2+and ROS content,decreased mitochondrial membrane potential(P<0.05,P<0.01),increased GPX4 and SLC7A11 protein expression levels(P<0.01),and decreased ACSL4 protein expression levels(P<0.01)in TAMs.Conclusion Compound Weichang'an Decoction can inhibit gastric cancer,with potential mechanisms related to promoting TAMs ferroptosis.
丁亚杰;韩晨;周韦利;杨金祖
上海中医药大学附属龙华医院,上海 200032上海中医药大学附属龙华医院,上海 200032上海中医药大学附属龙华医院,上海 200032上海中医药大学附属龙华医院,上海 200032
医药卫生
复方胃肠安胃癌铁死亡肿瘤相关巨噬细胞
Compound Weichang'an Decoctiongastric cancerferroptosistumor-associated macrophage
《世界中西医结合杂志》 2026 (8)
1517-1522,6
上海市中医肿瘤临床医学研究中心项目(21MC1930500)国家中医药管理局高水平中医药重点学科建设项目(zyyzdxk-2023063)
评论